Survey: How payers use nonpayer generated data to make formulary decisions

October 19, 2017

External, non-payer generated data can inform formulary decision-making-if payers know their strengths and weaknesses.

Three Orphan Drug Program problems and how the FDA plans to fix them

October 11, 2017

Recently, FDA Commissioner Scott Gottlieb announced the FDA will move to close loopholes in the Orphan Drug Program. Here’s what you need to know.

Top considerations when determining whether to approve expensive drugs

March 30, 2017

Weighing the ethics of approving expensive cancer drugs for patients facing terminal disease is a multifaceted endeavor. Here are some recommendations.

Expedited FDA approval plays dominant role in drug approvals

March 30, 2017

Last year was a banner year for generic drug approvals by the FDA. Find out what’s in store for 2017.

Opinion: More industry-stakeholders play blame game for high drug costs

March 23, 2017

Our policy analyst weighs in on a new drug industry PR campaign that attempts to shift the blame for high drug costs.

How data analytics combats the opioid epidemic

December 25, 2016

Deaths due to opioid abuse have risen sharply-and show no signs of leveling off. Here’s how data analytics can prevent abuse and diversion.

Predictions for biosimilars: How market access will play out

September 09, 2016

Early planning to craft a comprehensive real-world evidence generation strategy can help support the real-world safety and effectiveness of biosimilars.

Antidepressant drug pipeline: What to know

August 29, 2016

There are promising developments in the pipeline for patients with treatment-resistant depression.

Top 4 pharmacy trends healthcare executives should watch

August 28, 2016

Managed Healthcare Executive conducted its first-ever managed care pharmacy survey during the second quarter of 2016 in partnership with Access Market Intelligence. Here’s a look at some of the key findings, with experts weighing in on the results.

Cardiovascular drugs: Current spending, future outlook

May 06, 2016

Cardiovascular drugs are among the most widely used, since their indications are far reaching and address conditions that are prevalent among a large population.